Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]

Group 1 - The company expects to achieve a shareholder profit of approximately HKD 60 million to HKD 70 million for the six months ending June 30, 2025, representing an increase of about 80% to 110% compared to the same period in 2024 [1] - The growth is primarily attributed to foreign exchange gains resulting from the appreciation of the RMB against the HKD during the review period [1] - In the same period of 2024, the company experienced a one-time foreign exchange loss of approximately HKD 21.93 million due to a reduction in paid-in capital at its subsidiary, Sanming Sanyuan District Minxin Microfinance Co., Ltd [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦不 發 表 任 何 聲 明，並 明 確 表 示， 概 不 對 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任 。 正面盈利預告 本公告乃由本公司根據《上市規則》第13.09條及《證券及期貨條例》 第XIVA部項下的內幕消息條文刊發。 本公司董事會（「董事會 」）謹此告知本公司股東（「股東」）及有意投資 者，根據董事會目前所得資料及對本集團截至2025年6月30日止六個月 的未 經審 核 綜 合 管 理 賬 目的 初步 評估 ， 本 集 團 預 期 可能 錄得 截至 2025 年 6月 30日 止 六 個 月 的 股 東 應 佔 溢 利 約 港 幣 6,000萬 元 至 港 幣 7,000萬 元 ， 比較2024年同期上升約80%至110%。 - 1 - 有關增 長主 要由 於回 顧期間 人民 幣兌 港元匯 率升 值而 錄得 匯兌收 ...

閩信集團有限公司 執行董事兼總經理 黃文胜 香港，2025 年 8 月 13 日 於本 公 告日 期，本公 司執 行 董事 為 王非 先生（ 主 席）及 黃 文 胜先 生（ 副主 席）； 非執 行 董事 為 韓孝 捷先 生、周 天行 先 生 及游 莉 女士；獨 立 非 執行 董 事為 葉 啟 明先 生 、張 文 海先 生及 梁 創順 先 生。 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦不 發 表 任 何 聲 明，並 明 確 表 示， 概 不 對 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任 。 董事會會議召開日期 閩信集團有限公司（「本公 司」）董事會（「董事 會」）宣佈，本公司將於 2025年8月28日(星期四)舉行董事會會議，藉以（其中包括）批准本公司 及其附屬公司截至2025年6月30日止六個月的中期業績及其刊發，以及 考慮派發中期股息（如有）。 承董事會命 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年7月31日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | 閩信集團有限公司 | | | | 呈交日期: | 2025年8月1日 | | | | I. 法定/註冊股本變動 不適用 | | | | FF301 第 1 頁 共 10 頁 v 1.1.1 (A). 股份期權（根據發行人的股份期權計劃） 不適用 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00222 | | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 597,257,252 | | 0 | | 597,257,25 ...

智通财经7月22日电，郑××（00222191）组（账户组号: B6005182）于2025年7月22日在集运指数（欧 线）期货（EC）2510合约上账户组日内开仓交易量超限第2次达到处理标准，上期能源决定对相关客户 采取限制其在相应合约上开仓1个月的监管措施。 ...

Group 1 - The stock price of Aotexun (002227) closed at 13.09 yuan on June 24, 2025, with a 10.0% increase and a turnover rate of 5.19% [1] - The trading volume was 127,500 lots, with a transaction amount of 162 million yuan [1] - The net inflow of main funds was 68.07 million yuan, accounting for 41.94% of the transaction amount, with large single net inflow of 73.34 million yuan [1] Group 2 - For the first quarter of 2025, Aotexun reported total operating revenue of 46.41 million yuan, a year-on-year decrease of 12.17%, and a net profit attributable to shareholders of 17.86 million yuan, down 22.34% year-on-year [1] - The company's current ratio is 1.279, quick ratio is 0.796, and debt-to-asset ratio is 36.87% [1] Group 3 - Aotexun was established in 1998 and is located in Shenzhen, primarily engaged in the manufacturing of electrical machinery and equipment [2] - The company has invested in 13 enterprises, participated in 2,307 bidding projects, and holds 19 trademark registrations and 165 patents [2]

Individual Company News - Li Auto (02015.HK) reported a total revenue of 25.9 billion yuan for Q1 2025, representing a year-on-year increase of 1.1%. Adjusted net profit was 1 billion yuan, down 20.5% year-on-year [1] - Sihuan Pharmaceutical (01093.HK) is in discussions with potential partners regarding licensing and collaboration in drug development, production, and commercialization [1] - SANY International (00631.HK) achieved a net profit of 636 million yuan in Q1, a year-on-year increase of 30.6%, driven by significant revenue growth in large port machinery, oil and gas equipment, silicon energy products, and overseas mining vehicle sales [1] - Minxin Group (00222.HK) has jointly established a partnership to invest in a national-level specialized and innovative technology enterprise [1] - China Orient Group (00581.HK) reported an operating profit of approximately 199 million yuan for Q1 after deducting financial costs [1] Pharmaceutical Sector News - Jiahe Biotech (06998.HK) received approval from the Chinese National Medical Products Administration for the market launch of the new drug GB491 [2] - Fosun Pharma (02196.HK) had its registration application for the drug Luwomeitini approved by the National Medical Products Administration [2] - Yum China (09987.HK) entered into a share repurchase agreement for a total buyback amount of approximately 510 million USD for the second half of the year [2]

Financial Performance - Profit before taxation for 2024 is HK$94,865,000, a significant increase from HK$29,761,000 in 2023, representing a growth of 218%[21] - Profit attributable to shareholders of the Company for 2024 is HK$87,696,000, up from HK$39,409,000 in 2023, indicating a growth of 122%[21] - The income tax expense for 2024 is reported at HK$7,169,000, compared to a credit of HK$9,648,000 in 2023, reflecting a change in tax position[21] - The company has experienced a decline in profit before taxation from HK$472,459,000 in 2022 to HK$29,761,000 in 2023, marking a decrease of 94%[21] - The five-year financial summary indicates a fluctuating trend in profitability, with the highest profit attributable to shareholders recorded in 2021 at HK$495,931,000[21] - The Group recorded a profit attributable to shareholders of HK$87.7 million for the year ended December 31, 2024, an increase of 122.5% compared to the previous year[29] - Basic earnings per share for 2024 was HK$0.1468[32] - The Group's profit attributable to shareholders increased by 122.5% to HK$87.7 million in 2024, compared to HK$39.41 million in 2023, with basic earnings per share rising to 14.68 HK cents from 6.6 HK cents[56] Asset Management - Total assets of the Group decreased by 2.8% to HK$8.92 billion at December 31, 2024, compared to HK$9.18 billion at the end of 2023[36] - The Group's share of profit after tax from Xiamen International Bank (XIB) was HK$130 million in 2024, a 97.1% increase from HK$65.95 million in 2023[37] - XIB contributed approximately 148.2% to the Group's results in 2024[34] - Total assets of XIB increased by 1.8% to RMB1,141.07 billion at December 31, 2024, compared to RMB1,120.42 billion at the end of 2023[38] - The net asset value per share of the Company was HK$13.09 at December 31, 2024, with about 81% derived from the investment in XIB[38] - The Group's banking business total assets accounted for 71% of the Group's total assets at December 31, 2024[38] Dividends and Shareholder Returns - The Group declared a final dividend of HK$0.09 per share for 2023, but no final dividend was recommended for 2024 due to market uncertainties[34] - Huaneng declared a final dividend of RMB0.2 per share for 2023, with the Group recording dividend income of RMB13.59 million in 2024[79] - The board recommended a final dividend of RMB0.27 per share for 2024[80] Strategic Initiatives - The company is focusing on market expansion and new product development as part of its strategic initiatives for future growth[21] - The company is actively pursuing mergers and acquisitions to enhance its market position and drive growth[21] - The Group plans to continue investing in innovative technology and strategic transformation to enhance service quality and underwriting professionalism in a competitive market[49] - The Group maintained a focus on prudent business development and diversification of income sources amid ongoing global uncertainties[28] Risk Management - The financial report highlights a need for improved risk management and internal controls to mitigate future financial uncertainties[21] - The Group identified various risks and uncertainties that may affect its business and financial condition, which are not exhaustive[125] - The Group's business activities are exposed to various insurance and financial risks, including market risk (foreign exchange, price, and interest rate risks), credit risk, and liquidity risk[130] - Compliance with applicable laws and regulations may restrict the operations of the Group's insurance business and require significant resources for compliance efforts[132] Corporate Governance - The company emphasizes high standards of corporate governance to achieve business objectives and sustainable development[180] - The board of directors believes the company has complied with all applicable code provisions of the Corporate Governance Code for the year ending December 31, 2024[181] - The Group is committed to establishing a comprehensive financial service platform integrating resources from Fujian, Hong Kong, and Macau, driven by finance and industry[185] - The Board comprises eight members, including two Executive Directors, three Non-executive Directors, and three Independent Non-executive Directors, ensuring a balanced mix of skills and experiences[194] - The Group has adopted a Board Diversity Policy to enhance Board effectiveness and corporate governance, considering factors such as gender, age, and professional experience[198] Leadership and Management - The management team has undergone changes, with a new General Manager appointed on March 29, 2024, indicating potential shifts in operational strategy[7] - The company has a strong leadership team with extensive experience in banking and financial institutions management, enhancing its operational capabilities[146][150][153] - The company is focused on capital operations and financial management, with key personnel holding senior positions in various financial institutions[146][153] - The leadership team includes members with significant experience in investment management and corporate governance, which is crucial for future growth[146][150][153] Environmental, Social, and Governance (ESG) - The Group recognizes the significance of sound Environmental, Social, and Governance (ESG) practices and has integrated ESG considerations into daily operations[193] - The Board plays a key role in overseeing ESG strategy and has established a governance structure to manage sustainability and ESG-related issues[193] - The Group's ESG policies and performance will be detailed in a separate ESG Report available on the Company's website[193]

Financial Performance - The company's net profit attributable to shareholders reached HKD 87.7 million, an increase of 122.5% compared to the previous year[5] - Basic earnings per share were HKD 14.68, up from HKD 6.60 in the previous year[6] - Total revenue increased to HKD 226.6 million, a rise of 5.4% from HKD 214.6 million[6] - Operating profit improved to HKD 8.2 million, compared to HKD 3.6 million in the previous year[6] - The company reported a significant increase in dividend income, rising to HKD 16.4 million from HKD 2.7 million[6] - The total comprehensive income for the year was a loss of HKD 188.8 million, compared to a loss of HKD 120.3 million in the previous year[7] - The company’s net profit for the year was HKD 87,696,000, compared to HKD 39,409,000 in 2023, marking a significant increase of about 122%[25] - The basic earnings per share for 2024 was HKD 0.1468, up from HKD 0.066 in 2023, representing an increase of HKD 0.0808[47] Assets and Liabilities - Total assets decreased by 2.8% to HKD 8.92 billion[8] - Total equity attributable to shareholders fell by 3.1% to HKD 7.82 billion[9] - The total assets of the company reached HKD 9,184,725,000 in 2024, compared to HKD 8,915,071,000 in 2023, reflecting a growth of approximately 3%[25] - The company’s total liabilities were HKD 1,096,924,000 in 2024, slightly down from HKD 1,115,275,000 in 2023, indicating a decrease of about 1.6%[25] - As of December 31, 2024, total liabilities amounted to HKD 1,096.92 million, a decrease from HKD 1,115.28 million in 2023, representing 14% of total equity (2023: 13.8%)[62] Segment Performance - The group reports its performance based on segments that include financial services, insurance, property investment, and strategic investments[21] - The financial services segment includes banking operations in mainland China, Hong Kong, and Macau, as well as micro-lending activities in mainland China[21] - The insurance segment encompasses general insurance operations in Hong Kong and Macau[21] - The financial services segment recorded an after-tax profit of HKD 107.73 million in 2024, up 93.7% from HKD 55.63 million in 2023[48] - The insurance services segment achieved a profit of HKD 21.42 million for the fiscal year, an increase of 85.9% compared to HKD 11.52 million in 2023[44] Income and Expenses - Interest income for the year was HKD 49,538,000, up from HKD 44,446,000 in 2023, indicating an increase of about 11.8%[26] - The company’s administrative expenses decreased to HKD 53,730,000 in 2024 from HKD 56,566,000 in 2023, a reduction of approximately 5%[25] - The company reported a total of HKD 36,922,000 in other income for 2024, an increase from HKD 34,239,000 in 2023, representing a growth of about 7.9%[26] - The company’s financial costs were reported at HKD 41,366,000 for 2024, a decrease from HKD 44,154,000 in 2023, reflecting a reduction of about 6.4%[25] - The group’s employee costs, including directors' remuneration, decreased to HKD 40,695,000 in 2024 from HKD 42,517,000 in 2023[29] Dividends and Recommendations - The group did not recommend a final dividend for the year ended December 31, 2024, compared to a final dividend of HKD 0.09 per share totaling HKD 53,753,152.68 in 2023[38] - The company did not recommend a final dividend for the fiscal year 2024 due to market challenges and to retain cash for future investment opportunities[42] Financial Reporting and Compliance - The company has submitted consolidated financial statements for the year ending December 31, 2023, and will submit the statements for the year ending December 31, 2024, at an appropriate time[12] - The auditors have issued reports on the consolidated financial statements for both years without any reservations or matters of emphasis[12] - The adoption of the revised Hong Kong accounting standards did not have a significant impact on the group's financial performance or position for the current or prior periods[14] - The group has not early adopted new standards that are not yet effective, which are expected to have no significant impact on the group's financial condition or performance[16] - The audit committee, consisting of three independent non-executive directors, has reviewed the accounting principles and methods adopted by the group[83] Market and Economic Conditions - The group maintained a cautious optimism regarding business growth and financial performance for the fiscal year 2025, focusing on prudent risk management and business diversification[45] - The group is subject to various insurance and financial risks, including market risk, credit risk, and liquidity risk[73] Miscellaneous - The company has not repurchased, sold, or redeemed any of its issued shares during the year[79] - The group employed 70 staff members as of December 31, 2024, with compensation based on individual performance and qualifications[68] - The group had no significant contingent liabilities as of December 31, 2024, and 2023[67]